Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...

A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly ...

Sanofi said it is the third-largest business worldwide in the market for over-the-counter medicines, vitamins and supplements. CD&R -- which has a battery of investments in France -- would help ...

The breakthrough came after the investment group provided France with guarantees on maintaining jobs and production in the country following the talks between Sanofi, CD&R and the government ...

Sanofi (Symbol: SNY) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. France is taking a small stake in Sanofi’s consumer healthcare business in order to quell a political ...

The breakthrough came after the investment group provided France with guarantees on maintaining jobs and production in the country following the talks between Sanofi, CD&R and the government, the ...

Clayton Dubilier & Rice is close to completing a deal to buy control of Sanofi’s (NASDAQ ... interest in the OTC unit as part of the deal. France’s demands on employment, production and ...